GlaxoSmithKline puts emerging markets chief Hussain in charge of global pharma ops

With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too. The company is shifting current R&D chief Moncef Slaoui to the top of the new-and-larger vaccines business, and emerging markets head Abbas Hussain will take over the pharma business, overseeing U.S. chief Dierdre Connelly. Report

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.